Agios Pharmaceuticals, Inc.
AGIO· Nasdaq
AGIOAgios Pharmaceuticals, Inc.
Filed Feb 13, 2025 · 10-K · 44 days after period end · 0001439222-25-000009
derived · Computed from the longer spans the company filed.
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021 |
|---|---|---|---|---|
| Revenue | $10.73M | $7.10M | $4.31M | $0.00 |
| Net Income | -$96.52M | -$95.94M | $36.53M | -$94.63M |
| EPS Diluted | — | — |
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
| — |
| -$1.74 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2024 · filed Feb 13, 2025 · 44 d after period end
